Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer

NCT07528430 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT07528430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07528430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer
Lead sponsor
University of Maryland, Baltimore
Phase
Observational
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
November 30, 2032
Enrollment
450 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, advanced or metastatic